Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity
- 18 February 2011
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (10) , 4117-4122
Abstract
Chemotherapy-induced broad toxicities are the leading cause of the drug-induced mortality in cancer patients. Antiangiogenic drugs (ADs) in combination with chemotherapy are widely used as front-line therapy for the treatment of various human cancers. However, the beneficial mechanisms underlying combination therapy are poorly understood. Here we show that, in several murine tumor models, administration of sunitinib markedly reduced chemotherapy-induced bone marrow toxicity. Intriguingly, in a sequential treatment regimen, delivery of ADs followed by chemotherapy demonstrated superior survival benefits compared with simultaneous administration of two drugs. In murine tumor models, we show that VEGF increased chemotoxicity by synergistically suppressing bone marrow hematopoiesis with cytostatic drugs. These findings shed light on molecular mechanisms by which ADs in combination with chemotherapy produce survival benefits in cancer patients and provide conceptual information guiding future designs of clinical trials, current practice, and optimization of ADs for the treatment of cancer.Keywords
This publication has 23 references indexed in Scilit:
- Antiangiogenic therapies in breast cancer.2009
- Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculatureProceedings of the National Academy of Sciences, 2009
- Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistanceSeminars in Cancer Biology, 2009
- Drug markers questionedNature, 2008
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Placenta Growth Factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimersCancer Cell, 2002
- Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndromeProceedings of the National Academy of Sciences, 2001
- Carboplatin versus cisplatin in solid tumors: An analysis of the literatureAnnals of Oncology, 1998